The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas

British Journal of Haematology

Volumn 144, Issue 3, 2009, Pages 358-366

  Abramson, Jeremy S ^a,c   Chen, Wen ^a   Juszczynski, Przemyslaw ^a   Takahashi, Hidenobu ^a   Neuberg, Donna ^a   Kutok, Jeffery L ^b   Takeyama, Kunihiko ^a   Shipp, Margaret A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

AKT; Client; Heat shock protein 90; IPI 504; Lymphoma

Indexed keywords

ADENOSINE TRIPHOSPHATE; DOXORUBICIN; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 90; LY 24009; PROTEIN KINASE B; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION PROFILING; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 58449136915     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07484.x     Document Type: Article

References (52)

1. Abramson, J. Shipp, M. (2005) Advances in the biology and therapy of diffuse large B-cell lymphoma - moving towards a molecularly targeted approach. Blood, 106, 1164 1174.
2. Bagatell, R., Beliakoff, J., David, C.L., Marron, M.T. Whitesell, L. (2005) Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. International Journal of Cancer, 113, 179 188.
3. Basso, A.D., Solit, D.B., Chiosis, G., Giri, B., Tsichlis, P. Rosen, N. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. Journal of Biological Chemistry, 277, 39858 39866.
4. Bauwens, D., Hantson, P., Laterre, P.F., Michaux, L., Latinne, D., De Tourtchaninoff, M., Cosnard, G. Hernalsteen, D. (2005) Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxide-preserved stem cell infusion. Leukaemia & Lymphoma, 46, 1671 1674.
5. Chadli, A., Felts, S.J. Toft, D.O. (2008) GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity. Journal of Biological Chemistry, 283, 9509 9512.
6. Chang, H., Blondal, J.A., Benchimol, S., Minden, M.D. Messner, H.A. (1995) p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leukaemia & Lymphoma, 19, 165 171.
7. Chen, L., Monti, S., Juszczynski, P., Chen, W., Kutok, J.L. Shipp, M.A. (2008) SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood, 111, 2230 2237.
8. Chou, T.C. Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27 55.
9. Demetri, G.D., George, S., Morgan, J.A., van den Abbeele, A., Quigley, M.T., Fletcher, J.A., Normant, E., Patterson, J., Adams, J. Grayzel, D.S. (2006) Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patients with metastatic GIST: results of a Phase I Trial of IPI504, a water-soluble Hsp90 inhibitor. European Journal of Cancer Supplements, 4, 173.
10. Eustace, B.K., Sakurai, T., Stewart, J.K., Yimlamai, D., Unger, C., Zehetmeier, C., Lain, B., Torella, C., Henning, S.W., Beste, G., Scroggins, B.T., Neckers, L., Ilag, L.L. Jay, D.G. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nature Cell Biology, 6, 507 514.
11. Feuerhake, F., Kutok, J., Monti, S., Chen, W., LaCasce, A., Cattoretti, G., Kurtin, P., Pinkus, G.S., de Leval, L., Harris, N., Savage, K., Neuberg, D., Habermann, T., Dalla-Favera, R., Golub, T., Aster, J. Shipp, M. (2005) NFkB activity, function and target gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood, 106, 1392 1399.
12. Francis, L.K., Alsayed, Y., Leleu, X., Jia, X., Singha, U.K., Anderson, J., Timm, M., Ngo, H., Lu, G., Huston, A., Ehrlich, L.A., Dimmock, E., Lentzsch, S., Hideshima, T., Roodman, G.D., Anderson, K.C. Ghobrial, I.M. (2006) Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clinical Cancer Research, 12, 6826 6835.
13. Ge, J., Normant, E., Porter, J.R., Ali, J.A., Dembski, M.S., Gao, Y., Georges, A.T., Grenier, L., Pak, R.H., Patterson, J., Sydor, J.R., Tibbitts, T.T., Tong, J.K., Adams, J. Palombella, V.J. (2006) Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17- demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Journal of Medicinal Chemistry, 49, 4606 4615.
14. Gelderblom, H., Verweij, J., Nooter, K. Sparreboom, A. (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37, 1590 1598.
15. Georgakis, G.V., Li, Y., Rassidakis, G.Z., Medeiros, L.J. Younes, A. (2006a) The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Experimental Hematology, 34, 1670 1679.
16. Georgakis, G.V., Li, Y. Younes, A. (2006b) The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. British Journal of Haematology, 135, 68 71.
17. Georgakis, G.V., Li, Y., Rassidakis, G.Z., Martinez-Valdez, H., Medeiros, L.J. Younes, A. (2006c) Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clinical Cancer Research, 12, 584 590.
18. Georgakis, G.V., Li, Y., Rassidakis, G.Z., Medeiros, L.J., Mills, G.B. Younes, A. (2006d) Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. British Journal of Haematology, 132, 503 511.
19. Grem, J.L., Morrison, G., Guo, X.D., Agnew, E., Takimoto, C.H., Thomas, R., Szabo, E., Grochow, L., Grollman, F., Hamilton, J.M., Neckers, L. Wilson, R.H. (2005) Phase I and pharmacologic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with solid tumors. Journal of Clinical Oncology, 23, 1885 1893.
20. Grenert, J.P., Sullivan, W.P., Fadden, P., Haystead, T.A., Clark, J., Mimnaugh, E., Krutzsch, H., Ochel, H.J., Schulte, T.W., Sausville, E., Neckers, L.M. Toft, D.O. (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. Journal of Biological Chemistry, 272, 23843 23850.
21. Higman, M.A., Port, J.D., Beauchamp, Jr., N.J. Chen, A.R. (2000) Reversible leukoencephalopathy associated with re-infusion of DMSO preserved stem cells. Bone Marrow Transplantation, 26, 797 800.
22. Huston, A., Leleu, X., Jia, X., Moreau, A.S., Ngo, H.T., Runnels, J., Anderson, J., Alsayed, Y., Roccaro, A., Vallet, S., Hatjiharissi, E., Tai, Y.T., Sportelli, P., Munshi, N., Richardson, P., Hideshima, T., Roodman, D.G., Anderson, K.C. Ghobrial, I.M. (2008) Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clinical Cancer Research, 14, 865 874.
23. Isaacs, J.S., Xu, W. Neckers, L. (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell, 3, 213 217.
24. Jane, E.P. Pollack, I.F. (2008) The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Letters, 268, 46 55.
25. Jeon, Y.K., Park, C.H. Kim, K. (2007) The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T cell lymphoma by Akt down-regulation. Journal of Pathology, 213, 170 179.
26. Johnson, A.J., Wagner, A.J., Cheney, C.M., Smith, L.L., Lucas, D.M., Guster, S.K., Grever, M.R., Lin, T.S. Byrd, J.C. (2007) Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 139, 837 844.
27. Juszczynski, P., Kutok, J.L., Li, C., Mitra, J., Aguiar, R.C. Shipp, M.A. (2006) BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Molecular and Cellular Biology, 26, 5348 5359.
28. Kuo, C.C., Liang, C.M., Lai, C.Y. Liang, S.M. (2007) Involvement of heat shock protein (Hsp)90 beta but not Hsp90 alpha in antiapoptotic effect of CpG-B oligodeoxynucleotide. Journal of Immunology, 178, 6100 6108.
29. Mesa, R.A., Loegering, D., Powell, H.L., Flatten, K., Arlander, S.J., Dai, N.T., Heldebrant, M.P., Vroman, B.T., Smith, B.D., Karp, J.E., Eyck, C.J., Erlichman, C., Kaufmann, S.H. Karnitz, L.M. (2005) Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 106, 318 327.
30. Millson, S.H., Truman, A.W., Rácz, A., Hu, B., Panaretou, B., Nuttall, J., Mollapour, M., Söti, C. Piper, P.W. (2007) Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol. FEBS Journal, 274, 4453 4463.
31. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Kung, A.L., Davies, F.E., Morgan, G., Akiyama, M., Shringarpure, R., Munshi, N.C., Richardson, P.G., Hideshima, T., Chauhan, D., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Rosen, N.S. Anderson, K.C. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood, 107, 1092 1100.
32. Monti, S., Savage, K.J., Kutok, J.L., Feuerhake, F., Kurtin, P., Mihm, M., Wu, B., Pasqualucci, L., Neuberg, D., Aguiar, R.C., Dal Cin, P., Ladd, C., Pinkus, G.S., Salles, G., Harris, N.L., Dalla-Favera, R., Habermann, T.M., Aster, J.C., Golub, T.R. Shipp, M.A. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 105, 1851 1861.
33. Picard, D. (2004) Hsp90 invades the outside. Nature Cell Biology, 6, 479 480.
34. Polo, J.M., Juszczynski, P., Monti, S., Cerchietti, L., Ye, K., Greally, J.M., Shipp, M. Melnick, A. (2007) Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 104, 3207 3212.
35. Prodromou, C., Roe, S.M., O'Brien, R., Ladbury, J.E., Piper, P.W. Pearl, L.H. (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell, 90, 65 75.
36. Robertson, M.J., Kahl, B.S., Vose, J.M., de Vos, S., Laughlin, M., Flynn, P.J., Rowland, K., Cruz, J.C., Goldberg, S.L., Musib, L., Darstein, C., Enas, N., Kutok, J.L., Aster, J.C., Neuberg, D., Savage, K.J., LaCasce, A., Thornton, D., Slapak, C.A. Shipp, M.A. (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. Journal of Clinical Oncology, 25, 1741 1746.
37. Robles, A.L., Wright, M.H., Gandhi, B., Feis, S.S., Hanigan, C.L., Wiestner, A. Varticovski, L. (2006) Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis in p53-mutant lymphoma cell lines. Clinical Cancer Research, 12, 6547 6556.
38. Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N. Hartl, F.U. (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 93, 14536 14541.
39. Schulte, T.W. Neckers, L.M. (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemotherapy and Pharmacology, 42, 273 279.
40. Siegel, D., Jagannath, S., Mazumder, A., Vesole, D., Borrello, I., Sydor, J.R., Wright, J., Patterson, J., Normant, E., Adams, J., Anderson, K.C., Grayzel, D.S. Richardson, P.G. (2006) Update on Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 108, Abstract 3579.
41. Smith, P.G., Wang, F., Wilkinson, K.N., Savage, K.J., Klein, U., Neuberg, D.S., Bollag, G., Shipp, M.A. Aguiar, R.C.T. (2005) The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood, 105, 308 316.
42. Solit, D.B., Basso, A.D., Olshen, A.B., Scher, H.I. Rosen, N. (2003) Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Research, 63, 2139 2144.
43. Sreedhar, A.S., Kalmar, E., Csermely, P. Shen, Y.F. (2004) Hsp90 isoforms: functions, expression and clinical importance. FEBS Letters, 562, 11 15.
44. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U. Pavletich, N.P. (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89, 239 250.
45. Supko, J.G., Hickman, R.L., Grever, M.R. Malspeis, L. (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemotherapy and Pharmacology, 36, 305 315.
46. Sydor, J.R., Normant, E., Pien, C.S., Porter, J.R., Ge, J., Grenier, L., Pak, R.H., Ali, J.A., Dembski, M.S., Hudak, J., Patterson, J., Penders, C., Pink, M., Read, M.A., Sang, J., Woodward, C., Zhang, Y., Grayzel, D.S., Wright, J., Barrett, J.A., Palombella, V.J., Adams, J. Tong, J.K. (2006) Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proceedings of the National Academy of Sciences of the United States of America, 103, 17408 17413.
47. Taherian, A., Krone, P.H. Ovsenek, N. (2008) A comparison of Hsp90alpha and Hsp90beta interactions with cochaperones and substrates. Biochemistry and Cell Biology, 86, 37 45.
48. Uddin, S., Hussain, A.R., Al-Hussein, K.A., Manogaran, P.S., Wickrema, A., Gutierrez, M.I. Bhatia, K.G. (2005) Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clinical Cancer Research, 11, 3102 3108.
49. Whitesell, L. Lindquist, S.L. (2005) HSP90 and the chaperoning of cancer. Nature Reviews Cancer, 5, 761 772.
50. Whitesell, L., Mimnaugh, E.G., De Costa, B., Myers, C.E. Neckers, L.M. (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 91, 8324 8328.
51. Windrum, P. Morris, T.C. (2003) Severe neurotoxicity because of dimethyl sulphoxide following peripheral blood stem cell transplantation. Bone Marrow Transplantation, 31, 315.
52. Yao, Q., Weigel, B. Kersey, J. (2007) Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clinical Cancer Research, 13, 1591 1600.